ACADIA Pharmaceuticals Insider Sells Over $22,000 in Stock

James Kihara, an insider at the biopharmaceutical company, reduced his stake by 3.56%.

Apr. 9, 2026 at 9:34am

Got story updates? Submit your updates here. ›

An extreme close-up of complex, industrial-looking pharmaceutical manufacturing equipment and machinery, conveying the technical and operational nature of the biopharmaceutical industry.An insider's sale of over $22,000 in ACADIA Pharmaceuticals stock provides a data point for investors to consider as they evaluate the company's financial health and future prospects.San Diego Today

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) insider James Kihara sold 1,030 shares of the company's stock on Tuesday, April 7th. The shares were sold at an average price of $22.20, for a total transaction of $22,866.00. Following the sale, Kihara now owns 27,865 shares of the company's stock, valued at approximately $618,603.

Why it matters

Insider transactions, such as stock sales, can provide insights into how company insiders view the business's prospects. While a single sale does not necessarily indicate a negative outlook, tracking insider activity can help investors assess management's confidence in the company's future performance.

The details

The stock sale represented a 3.56% decrease in Kihara's position. ACADIA Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders, including Parkinson's disease psychosis, Alzheimer's disease psychosis, and schizophrenia.

  • The stock sale occurred on Tuesday, April 7th, 2026.

The players

James Kihara

An insider at ACADIA Pharmaceuticals Inc. who sold 1,030 shares of the company's stock.

ACADIA Pharmaceuticals Inc.

A biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders.

Got photos? Submit your photos here. ›

The takeaway

This insider sale provides a data point for investors to consider as they evaluate ACADIA Pharmaceuticals' prospects, though a single transaction does not necessarily indicate a broader trend or the company's overall outlook.